SCHEMBL16010302

SCHEMBL16010302

CC(C)OCCNC(=O)c1c(O)c2ncc(Cc3ccc(F)cc3)cc2n(CCCN(C)C(=O)O)c1=O

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.38
KMT2A Q03164 7/20 0.36
MEN1 O00255 6/20 0.36
CNR2 P34972 2/20 0.36
LMNA P02545 2/20 0.35
POLB P06746 2/20 0.34
HIF1A Q16665 1/20 0.34
LTA4H P09960 1/20 0.33
KDM4E B2RXH2 1/20 0.33
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5547225 0.92 L3MBTL1 (0.36) L3MBTL1KMT2AMEN1CNR2LMNA
SCHEMBL5546941 0.91 L3MBTL1 (0.40) L3MBTL1KMT2AMEN1LMNAPOLB
SCHEMBL5547444 0.90 KMT2A (0.37) L3MBTL1KMT2AMEN1CNR2LMNA
SCHEMBL5546979 0.90 L3MBTL1 (0.40) L3MBTL1KMT2AMEN1CNR2LMNA
SCHEMBL5545838 0.90 L3MBTL1 (0.40) L3MBTL1KMT2AMEN1CNR2LMNA
SCHEMBL16010305 0.89 L3MBTL1 (0.39) L3MBTL1KMT2AMEN1CNR2LMNA
SCHEMBL5545794 0.89 KDM4E (0.40) L3MBTL1KMT2AMEN1CNR2LMNA
SCHEMBL5548593 0.89 L3MBTL1 (0.41) L3MBTL1KMT2AMEN1CNR2LMNA
SCHEMBL5548089 0.87 L3MBTL1 (0.40) L3MBTL1KMT2AMEN1CNR2LMNA
SCHEMBL5546654 0.87 L3MBTL1 (0.40) L3MBTL1KMT2AMEN1CNR2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 L3MBTL1 1411/4885KMT2A 502/4885MEN1 4802/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 L3MBTL1 1408/4885KMT2A 819/4885MEN1 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.